Biomedical Engineering Reference
In-Depth Information
afflicted mice following treatment with a tolerogenic peptide.
J. Autoimmun. 34, 87-95.
83. Sharabi A, Zinger H, Zborowsky M, Sthoeger ZM, Mozes E.
(2006) A peptide based on the complementarity-determining
region 1 of an autoantibody ameliorates lupus by up-regulating
CD4
þ
CD25
þ
cells and TGF-beta. Proc. Natl. Acad. Sci. USA
103, 8810-8815.
84. Hahn BH, Singh RP, La Cava A, Ebling FM. (2005) Tol-
erogenic treatment of lupus mice with consensus peptide
induces Foxp3-expressing, apoptosis-resistant, TGFbeta-
secreting CD8
þ
T cell suppressors. J.
86. van Schouwenburg PA, Bartelds GM, Hart MH, Aarden L,
Wolbink GJ, Wouters D. (2010) A novel method for the
detection of antibodies to adalimumab in the presence of
drug reveals “hidden” immunogenicity in rheumatoid arthritis
patients. J. Immunol. Methods. 362, 82-88.
87. Swanson SJ. (2006) Immunogenicity issues in drug develop-
ment. J. Immunotoxicol. 3, 165-172.
88. Moxness M, Tatarewicz S, Weeraratne D, Murakami N,
Wullner D, Mytych D, et al. (2005) Immunogenicity testing
by electrochemiluminescent detection for antibodies directed
against therapeutic human monoclonal antibodies. Clin. Chem.
51, 1983-1985.
89. Koren E. (2002) From characterization of antibodies to pre-
diction of immunogenicity. Dev. Biol. (Basel) 109, 87-95.
Immunol. 175,
7728-7737.
85. Hanvesakul R, Maillere B, Briggs D, Baker R, Larche M, Ball
S. (2007) Indirect recognition of T-cell epitopes derived from
the alpha 3 and transmembrane domain of HLA-A2. Am. J.
Transplant. 7, 1148-1157.
Search WWH ::
Custom Search